Clinical Scorecard: Phase II Trial Investigating Initial Helicobacter pylori Eradication Treatment for Early-Stage Extragastric Mucosa-Associated Lymphoid Tissue Lymphoma

At a Glance

Key Highlights

• Overall response rate (ORR) of 65.4% in 26 patients (source needed)

• Complete remission (CR) achieved in 38.5% of patients (source needed)

• Median duration of lymphoma-free survival was 78.8 months for CR patients (source needed)

• 7-year event-free survival rate of 76.5% (source needed)

• 7-year overall survival rate of 95.8% (source needed)

Guideline-Based Recommendations

Diagnosis

• HP infection confirmed by 13C-urea breath test, serology test, or histology (source needed)

Management

• Frontline HPE regimens including lansoprazole, amoxicillin, clarithromycin, and metronidazole (source needed)

Monitoring & Follow-up

• Follow-up every 3 months for PR or stable disease; every 6 months for CR (source needed)

Risks

• Potential progression of lymphoma if no tumor shrinkage is observed (source needed)

Patient & Prescribing Data

26 patients with localized extragastric MALT lymphoma

Sequential HPE regimens resulted in significant response rates

Clinical Best Practices

• Regular follow-ups with imaging studies for monitoring (source needed)

• Consider second-line treatments for patients with stable disease or progression (source needed)

Related Resources & Content

• Testerman et al. Review on Helicobacter pylori

• Phase II Trial Registration

---